The global nedaplatin injection market is expected to grow at a significant CAGR during the forecast period (2021-2027).  Nedaplatin (INN, also known as Aqupla) is a platinum-based antineoplastic drug that is used in cancer chemotherapy. Non-small cell lung cancer (NSCLC), small cell lung cancer, esophageal cancer, and head and neck tumours are all treated with this drug. In cancer cells, nedaplatin destroys DNA and causes cell death. It also acts as a radiosensitizer, making the afflicted cells more susceptible to radiation therapy. The rising prevalence of esophageal cancer and NSCLC is contributing to the growth of the market. As per the estimates for esophageal cancer by the American Cancer Society for 2021 in the US, a total of 19,260 new cases of esophageal cancer have been identified (15,310 in men and 3,950 in women) Esophageal cancer claimed the lives of 15,530 people (12,410 in men and 3,120 in women). Men are more likely than women to develop esophageal cancer. In the US, the lifetime risk of developing esophageal cancer is roughly 1 in 125 for males and 1 in 417 for women. 

Cancer accounts for around 1% of all cancer diagnoses, however, it is far more common in other parts of the world, such as Iran, northern China, India, and Southern Africa. Further, the most frequent kind of lung cancer is NSCLC, which accounts for 84% of all lung cancer diagnoses. Since the mid-2000s, incidence rates in the US have decreased by about 2% each year. Since the mid-1980s, the number of new lung cancer cases among men has been steadily decreasing. In the mid-2000s, the number of new cases identified each year in women began to decline. Men's rates of cancer are declining quicker than women. Lung cancer is 15% more common in black males than in white men. When compared to white women, black women have a 14% lower risk of lung cancer. The condition is more likely to strike people over the age of 65. The average age at which a person is diagnosed is 70. Lung cancer is the second most frequent cancer in men and women and the major cause of cancer death. This disease is expected to kill 131,880 people (69,410 men and 62,470 women) in the US this year. Nedaplatin (NDP) has been widely used for the treatment of patients with non-small cell lung cancer (NSCLC) over the last decade. In addition, nedaplatin in combination with docetaxel has demonstrated promising activity for advanced squamous cell lung carcinoma in clinical studies, which in turn, is also accelerating the market growth. 

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Product Type 

o By Application 

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape:   Jiangsu Simcere Pharmaceutical Co., Ltd., among others. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Nedaplatin Injection Market Report by Segment

By Product Type 

• 10 mg
• 50 mg
• 100 mg

By Application 

• Lung Cancer
• Esophageal Cancer
• Bladder Cancer
• Testicular Cancer
• Cervical Cancer
• Ovarian Cancer
• Others

Global Nedaplatin Injection Market by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa